Exozymes Inc.
EXOZ Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$3.75
KIRA · Stoqly’s AI analyst, in plain words
- Exozymes Inc. lost $9.2M in fiscal 2025.
- Free cash flow was −$6.7M in fiscal 2025, — of revenue.
Market cap
$32.5M
P/E
—
Revenue
—
Net income
−$9.2M
Free cash flow
−$6.7M
Operating margin
—
Exozymes Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$9.2M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Exozymes Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- EXOZYMES INC.
- CIK
- 0002010788
Exozymes Inc. · EXOZ
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | $0.1M | — | — |
| Operating margin | −2,562.3% | — | — |
| Net income | −$2.0M | −$5.9M | −$9.2M |
| Net margin | −2,907.8% | — | — |
| Diluted EPS | −$0.33 | −$0.89 | −$1.09 |
| Cash | |||
| Cash from operations | −$1.2M | −$8.5M | −$6.5M |
| Capital expenditure | $0.3M | $0.4M | $0.2M |
| Free cash flow | −$1.5M | −$8.9M | −$6.7M |
| FCF margin | −2,096.4% | — | — |
| Share count change | — | 5.0% | 27.7% |
| Debt and strength | |||
| Cash and short-term investments | $0.1M | $9.7M | $3.0M |
| Shareholders' equity | −$0.4M | $10.4M | $3.4M |
| Current ratio | 0.5x | 8.1x | 2.5x |
| Returns and quality | |||
| Return on equity | — | −116.8% | −132.6% |
| Return on tangible equity | — | −56.2% | −269.6% |
| Altman Z'' | −11.3 | 2.9 | −18.5 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.0M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Exozymes Inc. · EXOZ
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.75 a share, the company is worth $32.5M.
Source: SEC EDGAR XBRL filings (CIK 0002010788). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.